MedTrace Logo

Adjuvant Therapy With CytoSorb in Refractory Septic Shock

NCT04013269 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2022-11-08

No results posted yet for this study

Summary

This prospective randomized single center study investigates to what extent the removal of elevated cytokine levels by hemoadsorption has a positive effect on the treatment of patients in septic shock by stabilizing the circulatory situation.

Conditions

  • Septic Shock

Interventions

DEVICE

CytoSorb-Therapy

Additional use of Cytosorb-Adsorber in patients with septic shock and need for continuous renal replacement therapy

Sponsors & Collaborators

  • CytoSorbents, Inc

    collaborator INDUSTRY

  • Universitätsklinikum Hamburg-Eppendorf

    lead OTHER

Principal Investigators

  • Stefan Kluge, MD · University Hospital Hamburg-Eppendorf, Department of Intensive Care Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04013269 on ClinicalTrials.gov